NasdaqGS:AGIOBiotechs
Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation
Agios Pharmaceuticals halted development of tebapivat in lower risk myelodysplastic syndromes after a Phase 2b trial did not meet internal efficacy thresholds.
The decision removes a candidate from Agios’s rare blood disorder pipeline and follows a review of trial data against the company’s internal benchmarks.
Agios plans to continue concentrating resources on its sickle cell disease program and broader portfolio in rare hematologic conditions.
For investors tracking NasdaqGS:AGIO, the...